MDS

GTB-3550 TriKE for the treatment of MDS & AML 1:57
GTB-3550 TriKE for the treatment of MDS & AML
Jeffrey S. Miller • 12 Nov 2021
Mechanism of action of GTB-3550 TriKE 1:48
Mechanism of action of GTB-3550 TriKE
Jeffrey S. Miller • 12 Nov 2021
Updates on the treatment of MDS 1:45
Updates on the treatment of MDS
Sangmin Lee • 20 Oct 2021
The use of DLI to prevent relapse 0:52
The use of DLI to prevent relapse
Christoph Schmid • 29 Sep 2021
Management of relapse following alloHSCT in patients with AML and MDS 2:47
Management of relapse following alloHSCT in patients with AML and MDS
Thomas Schröder • 5 Oct 2021
Update on lenalidomide for MDS 7:32
Update on lenalidomide for MDS
Valeria Santini • 23 Sep 2021
Novel targets in low-risk MDS 1:27
Novel targets in low-risk MDS
Sophie Park • 22 Sep 2021
Assessing response to ESAs and alternative therapies 5:25
Assessing response to ESAs and alternative therapies
Sophie Park • 22 Sep 2021
ESAs for the management of lower-risk MDS 2:37
ESAs for the management of lower-risk MDS
Sophie Park • 22 Sep 2021
Key advances in MDS management 1:22
Key advances in MDS management
Sandra Kurtin • 22 Sep 2021
The role of immune checkpoint inhibitors in MDS 4:27
The role of immune checkpoint inhibitors in MDS
Shahram Kordasti • 22 Sep 2021
Future directions in MDS 1:19
Future directions in MDS
Andrew Brunner • 13 Sep 2021
Evaluating therapies in MDS 3:38
Evaluating therapies in MDS
Andrew Brunner • 13 Sep 2021
An overview of the MDS diagnosis pathway 1:41
An overview of the MDS diagnosis pathway
Andrew Brunner • 13 Sep 2021
The treatment protocol for higher risk MDS 3:08
The treatment protocol for higher risk MDS
Andrew Brunner • 13 Sep 2021
Inflammatory signaling in the pathogenesis of MDS 3:19
Inflammatory signaling in the pathogenesis of MDS
David Sallman • 14 Sep 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals